{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:32:43Z","timestamp":1761823963257,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2018.01.082","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T08:00:36Z","timestamp":1518854436000},"page":"4663-4672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication"],"prefix":"10.1016","volume":"37","author":[{"given":"Andr\u00e1s","family":"Marosi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Forg\u00e1ch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Gyuranecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga M.","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Bakonyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.082_b0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.082_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2014.02.013","article-title":"Survival from rabies encephalitis","volume":"339","author":"De Souza","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.01.082_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2015.05.005","article-title":"Atypical rabies encephalitis in a six-year-old boy: clinical, radiological, and laboratory findings","volume":"36","author":"Karande","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0028-3886.156295","article-title":"Pituitary cachexia after rabies encephalitis","volume":"63","author":"Kumar","year":"2015","journal-title":"Neurol India"},{"key":"10.1016\/j.vaccine.2018.01.082_b0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcv.2015.07.003","article-title":"Unique clinical and imaging findings in a first ever documented PCR positive rabies survival patient: a case report","volume":"70","author":"Netravathi","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40779-016-0089-y","article-title":"Recovery from rabies, a universally fatal disease","volume":"3","author":"Manoj","year":"2016","journal-title":"Military Med Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0035","first-page":"66","article-title":"A case of human survival of rabies, South Africa","volume":"31","author":"Weyer","year":"2016","journal-title":"South Afr J Inf Dis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0040","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1056\/NEJMoa050382","article-title":"Survival after treatment of rabies with induction of coma","volume":"352","author":"Willoughby","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.082_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2013.01.003","article-title":"Current and future approaches to the therapy of human rabies","volume":"99","author":"Jackson","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.vaccine.2018.01.082_b0050","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1128\/JVI.79.12.7673-7681.2005","article-title":"Identification of the rabies virus alpha\/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3","volume":"79","author":"Brz\u00f3zka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0055","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1128\/JVI.80.6.2675-2683.2006","article-title":"Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2","volume":"80","author":"Brz\u00f3zka","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0060","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1128\/JVI.00011-10","article-title":"Role of interferon antagonist activity of rabies virus phosphoprotein in viral pathogenicity","volume":"84","author":"Ito","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0065","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1128\/JVI.01930-06","article-title":"The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1","volume":"81","author":"Vidy","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1348-0421.12058","article-title":"Rabies virus nucleoprotein functions to evade activation of the RIG-I-mediated antiviral response","volume":"57","author":"Masatani","year":"2010","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13365-011-0041-6","article-title":"The type I interferon response bridles rabies virus infection and reduces pathogenicity","volume":"17","author":"Chopy","year":"2011","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0080","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s00705-013-1743-2","article-title":"Wild-type rabies virus phosphoprotein is associated with viral sensitivity to type I interferon treatment","volume":"158","author":"Niu","year":"2013","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2851","article-title":"Antiviral therapy for human rabies","volume":"20","author":"Appolinario","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.vaccine.2018.01.082_b0090","first-page":"2","article-title":"Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice","volume":"2","author":"Appolinario","year":"2013","journal-title":"J Virol Antivir Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.01.082_b0100","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01219-10","article-title":"T-705 (favipiravir) inhibition of arenavirus replication in cell culture","volume":"55","author":"Mendenhall","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2018.01.082_b0105","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res"},{"issue":"8","key":"10.1016\/j.vaccine.2018.01.082_b0115","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"1","author":"Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.082_b0120","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0135","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiw174","article-title":"T-705 as a potential therapeutic agent for rabies","volume":"214","author":"Virojanapirom","year":"2016","journal-title":"J Infect Dis"},{"issue":"359","key":"10.1016\/j.vaccine.2018.01.082_b0140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"24","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.082_b0145","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0150","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1136\/gut.2009.182212","article-title":"New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication","volume":"58","author":"Himmelsbach","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.vaccine.2018.01.082_b0155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2015.03.012","article-title":"The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro","volume":"118","author":"Descamps","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0160","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1128\/JVI.79.18.11801-11812.2005","article-title":"Rabies virus-induced activation of mitogen-activated protein kinase and NF-kappaB signaling pathways regulates expression of CXC and CC chemokine ligands in microglia","volume":"79","author":"Nakamichi","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0165","first-page":"227","article-title":"The method of \u201cRight and wrong cases\u201d (constant stimuli) with Gauss\u2019 formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0175","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1128\/JCM.43.6.2786-2792.2005","article-title":"Development of a real-time, TaqMan reverse transcription-PCR assay for detection and differentiation of lyssavirus genotypes 1, 5, and 6","volume":"43","author":"Wakeley","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0180","first-page":"149","article-title":"Real-time polymerase chain reaction as a rapid and efficient alternative to estimation of picornavirus titers by tissue culture infectious dose 50% or plaque forming units","volume":"53","author":"Jonsson","year":"2009","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/1743-422X-9-311","article-title":"Development and validation of a Q-PCR based TCID50 method for human herpesvirus 6","volume":"9","author":"Gustafsson","year":"2012","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.01.082_b0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vetmic.2006.03.019","article-title":"Evaluation of antiviral activity of phenolic compounds and derivatives against rabies virus","volume":"116","author":"Ch\u00e1vez","year":"2006","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2009.07.012","article-title":"Inhibition of rabies virus replication by multiple artificial microRNAs","volume":"84","author":"Israsena","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0200","doi-asserted-by":"crossref","first-page":"e0140586","DOI":"10.1371\/journal.pone.0140586","article-title":"\u03bb-Carrageenan P32 is a potent inhibitor of rabies virus infection","volume":"10","author":"Luo","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.vaccine.2018.01.082_b0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0974-8490.188874","article-title":"Evaluation of In vitro Antiviral Activity of Datura metel Linn Against Rabies Virus","volume":"8","author":"Roy","year":"2016","journal-title":"Pharmacogn. Res"},{"key":"10.1016\/j.vaccine.2018.01.082_b0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1128\/jcm.27.3.519-523.1989","article-title":"Comparative field evaluation of the fluorescent-antibody test, virus isolation from tissue culture, and enzyme immunodiagnosis for rapid laboratory diagnosis of rabies","volume":"27","author":"Bourhy","year":"1989","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0215","doi-asserted-by":"crossref","first-page":"366","DOI":"10.4014\/jmb.1010.10003","article-title":"Proteomic profiles of mouse neuro N2a cells infected with variant virulence of rabies viruses","volume":"21","author":"Wang","year":"2011","journal-title":"J Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0220","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1590\/S1517-83822013005000050","article-title":"In vitro and in vivo inhibition of rabies virus replication by RNA interference","volume":"44","author":"Durymanova Ono","year":"2013","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0225","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nbd.2005.08.015","article-title":"Expression of the interferon-alpha\/beta-inducible bovine Mx1 dynamin interferes with replication of rabies virus","volume":"21","author":"Leroy","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0230","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13337-015-0269-5","article-title":"Exogenous interferon prolongs survival of rabies infected mice","volume":"26","author":"Mehta","year":"2015","journal-title":"VirusDis"},{"key":"10.1016\/j.vaccine.2018.01.082_b0235","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0769-2617(83)80048-3","article-title":"Effects of heteropolyanions and nucleoside analogues on rabies virus: in vitro study of syntheses and viral production","volume":"134","author":"Bussereau","year":"1983","journal-title":"Ann Inst Pasteur Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/sita.200600114","article-title":"Influenza viruses and MAP kinase cascades \u2013 Novel targets for an antiviral intervention?","volume":"7","author":"Ludwig","year":"2007","journal-title":"Signal Transduct."},{"key":"10.1016\/j.vaccine.2018.01.082_b0245","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1096\/fj.10-158766","article-title":"MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR","volume":"24","author":"Luig","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2018.01.082_b0250","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/jcp.25014","article-title":"GRP78\/Dna K is a target for nexavar\/stivarga\/votrient in the treatment of human malignancies, viral infections and bacterial diseases","volume":"230","author":"Roberts","year":"2015","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0255","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.082_b0260","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.082_b0265","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0006-291X(79)91853-9","article-title":"The broad spectrum antiviral agent ribavirin inhibits capping of mRNA","volume":"89","author":"Goswami","year":"1979","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2018.01.082_b0270","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.01.082_b0275","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1128\/JVI.00614-11","article-title":"Ribavirin can be mutagenic for arenaviruses","volume":"85","author":"Moreno","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.082_b0280","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:36Z","timestamp":1759401216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":56,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X18301555"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.082","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}